Chapter 2 34 Appendix B. Detailed overview of study endpoints Patient Event Days after procedure OAC Age (years)/ sex Prior stroke or TIA CHA2DS2VASc score HASBLED score Details event 1 TIA 2 Acenocoumarol 60/ F Yes 4 1 - 2 TIA 10 Acenocoumarol 63/ M No 3 2 - 3 TIA 22 Dabigatran 69/ F No 2 3 - 4 TIA 25 Acenocoumarol 82/ F Yes 7 4 - 5 TIA 39 Acenocoumarol 61/ M Yes 4 2 - 6 Stroke 4 Rivaroxaban 55/ M Yes 2 1 Thrombectomy, MRS 0 7 Stroke 16 Acenocoumarol 54/ M Yes 3 2 Failed thrombectomy, MRS 2 8 Stroke 22 Acenocoumarol 84/ M No 2 4 Switch to DOAC, MRS 1 9 Major bleed 2 Dabigatran 60/ M No 1 0 GI bleeding, blood transfusion and idarucizumab 10 Major bleed 12 Acenocoumarol 77/ M No 6 1 Subdural hematoma after fall, MRS 4 11 Major bleed 54 Edoxaban 75/ M No 4 2 Stoma bleeding, blood transfusion, prothrombin complex 12 Death 2 Acenocoumarol 66/ M Yes 5 4 SCD, ischemic cardiomyopathy 13 Death 3 Rivaroxaban 33/ M No 1 0 SCD, complex congenital heart disease 14 Death 4 Acenocoumarol 70/ M No 2 1 SCD 15 Death 8 Acenocoumarol 68/ M No 5 3 Death due to MI 16 Death 18 Edoxaban 85/ M No 5 2 Death due to heart failure 17 Death 24 Acenocoumarol 54/ F Yes 5 2 SCD, dilated cardiomyopathy 18 Death 31 Rivaroxaban 75/ F No 5 2 Death due to heart failure 19 Death 35 Acenocoumarol 68/ M No 5 3 Death due to MI Abbreviations: DOAC= direct oral anticoagulant, GI = gastro-intestinal; MI = myocardial infarction; MRS = modified Rankin scale, OAC= oral anticoagulant, SCD = sudden cardiac death, TIA=transient ischemic attack.
RkJQdWJsaXNoZXIy MTk4NDMw